204 related articles for article (PubMed ID: 37185332)
21. Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors.
Kropp KN; Fatho M; Huduti E; Faust M; Lübcke S; Lennerz V; Paschen A; Theobald M; Wölfel T; Wölfel C
Front Immunol; 2023; 14():1245559. PubMed ID: 37849763
[TBL] [Abstract][Full Text] [Related]
22. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
23. Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial.
Riccardo F; Tarone L; Camerino M; Giacobino D; Iussich S; Barutello G; Arigoni M; Conti L; Bolli E; Quaglino E; Merighi IF; Morello E; Dentini A; Ferrone S; Buracco P; Cavallo F
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580930
[TBL] [Abstract][Full Text] [Related]
24. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
[TBL] [Abstract][Full Text] [Related]
25. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
[TBL] [Abstract][Full Text] [Related]
26. CSPG4: a prototype oncoantigen for translational immunotherapy studies.
Rolih V; Barutello G; Iussich S; De Maria R; Quaglino E; Buracco P; Cavallo F; Riccardo F
J Transl Med; 2017 Jul; 15(1):151. PubMed ID: 28668095
[TBL] [Abstract][Full Text] [Related]
27. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins.
Eng MS; Kaur J; Prasmickaite L; Engesæter BØ; Weyergang A; Skarpen E; Berg K; Rosenblum MG; Mælandsmo GM; Høgset A; Ferrone S; Selbo PK
Photochem Photobiol Sci; 2018 May; 17(5):539-551. PubMed ID: 29565434
[TBL] [Abstract][Full Text] [Related]
28. VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen.
Nounamo B; Jousheghany F; Siegel ER; Post SR; Kelly T; Ferrone S; Kieber-Emmons T; Monzavi-Karbassi B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768830
[TBL] [Abstract][Full Text] [Related]
29. Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Märkl F; Benmebarek MR; Keyl J; Cadilha BL; Geiger M; Karches C; Obeck H; Schwerdtfeger M; Michaelides S; Briukhovetska D; Stock S; Jobst J; Müller PJ; Majed L; Seifert M; Klüver AK; Lorenzini T; Grünmeier R; Thomas M; Gottschlich A; Klaus R; Marr C; von Bergwelt-Baildon M; Rothenfusser S; Levesque MP; Heppt MV; Endres S; Klein C; Kobold S
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208128
[TBL] [Abstract][Full Text] [Related]
30. Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.
Uranowska K; Kalic T; Valtsanidis V; Kitzwögerer M; Breiteneder H; Hafner C
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649790
[TBL] [Abstract][Full Text] [Related]
31. Functional and clinical relevance of chondroitin sulfate proteoglycan 4.
Campoli M; Ferrone S; Wang X
Adv Cancer Res; 2010; 109():73-121. PubMed ID: 21070915
[TBL] [Abstract][Full Text] [Related]
32. CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response.
Boudin L; de Nonneville A; Finetti P; Mescam L; Le Cesne A; Italiano A; Blay JY; Birnbaum D; Mamessier E; Bertucci F
J Transl Med; 2022 Oct; 20(1):464. PubMed ID: 36221119
[TBL] [Abstract][Full Text] [Related]
33. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
Front Immunol; 2017; 8():1911. PubMed ID: 29375561
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical detection of the chondroitin sulfate proteoglycan 4 protein in primary and metastatic melanoma.
Grossauer A; Uranowska K; Kitzwögerer M; Mostegel M; Breiteneder H; Hafner C
Oncol Lett; 2023 Sep; 26(3):382. PubMed ID: 37559576
[TBL] [Abstract][Full Text] [Related]
35. Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells.
Harper JR; Bumol TF; Reisfeld RA
J Immunol; 1984 Apr; 132(4):2096-104. PubMed ID: 6199423
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2.
Pellizzari G; Martinez O; Crescioli S; Page R; Di Meo A; Mele S; Chiaruttini G; Hoinka J; Batruch I; Prassas I; Grandits M; López-Abente J; Bugallo-Blanco E; Ward M; Bax HJ; French E; Cheung A; Lombardi S; Figini M; Lacy KE; Diamandis EP; Josephs DH; Spicer J; Papa S; Karagiannis SN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34112739
[TBL] [Abstract][Full Text] [Related]
37. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
[TBL] [Abstract][Full Text] [Related]
38. Targeting CSPG4 for isolation of melanoma cell-derived exosomes from body fluids.
Ferrone S; Whiteside TL
HNO; 2020 Feb; 68(2):100-105. PubMed ID: 32006045
[TBL] [Abstract][Full Text] [Related]
39. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
Wang Y; Geldres C; Ferrone S; Dotti G
Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
[TBL] [Abstract][Full Text] [Related]
40. Constitutive and TNFα-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy.
Pellegatta S; Savoldo B; Di Ianni N; Corbetta C; Chen Y; Patané M; Sun C; Pollo B; Ferrone S; DiMeco F; Finocchiaro G; Dotti G
Sci Transl Med; 2018 Feb; 10(430):. PubMed ID: 29491184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
